In numerical terms, our latest recon of private market investment in the life sciences is about on par with the previous week: 13 deals with a total value of $987 million.
But there was a noticeable difference on the focus of the deals. Drugmakers (mostly in the biotechnology space) took the lion's share of funding in our previous tallies, but this time much of the funding accrues to digital health . . .
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available.